144 related articles for article (PubMed ID: 38006850)
21. Risk factors for development of lymphopenia in dimethyl fumarate-treated patients with multiple sclerosis.
Ravn J; Jensen HB; Kant M; Andersen PB; Góra MK; Sejbaek T
Mult Scler Relat Disord; 2022 Nov; 67():104081. PubMed ID: 35944466
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
Cohen JA; Comi G; Arnold DL; Bar-Or A; Selmaj KW; Steinman L; Havrdová EK; Cree BA; Montalbán X; Hartung HP; Huang V; Frohna P; Skolnick BE; Kappos L;
Mult Scler; 2019 Aug; 25(9):1255-1262. PubMed ID: 30043658
[TBL] [Abstract][Full Text] [Related]
23. Fingolimod for relapsing-remitting multiple sclerosis.
La Mantia L; Tramacere I; Firwana B; Pacchetti I; Palumbo R; Filippini G
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD009371. PubMed ID: 27091121
[TBL] [Abstract][Full Text] [Related]
24. Frequency and risk factors of rebound after fingolimod discontinuation - A retrospective study.
Maunula A; Atula S; Laakso SM; Tienari PJ
Mult Scler Relat Disord; 2024 Jan; 81():105134. PubMed ID: 37980790
[TBL] [Abstract][Full Text] [Related]
25. Warts and all: Fingolimod and unusual HPV-associated lesions.
Triplett J; Kermode AG; Corbett A; Reddel SW
Mult Scler; 2019 Oct; 25(11):1547-1550. PubMed ID: 30427266
[TBL] [Abstract][Full Text] [Related]
26. Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series.
Delgado S; Hernandez J; Tornes L; Rammohan K
BMC Neurol; 2021 Feb; 21(1):48. PubMed ID: 33530945
[TBL] [Abstract][Full Text] [Related]
27. Ozanimod (Zeposia) for multiple sclerosis.
Med Lett Drugs Ther; 2020 Aug; 62(1605):132-134. PubMed ID: 32970043
[No Abstract] [Full Text] [Related]
28. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.
Cohen JA; Arnold DL; Comi G; Bar-Or A; Gujrathi S; Hartung JP; Cravets M; Olson A; Frohna PA; Selmaj KW;
Lancet Neurol; 2016 Apr; 15(4):373-81. PubMed ID: 26879276
[TBL] [Abstract][Full Text] [Related]
29. Reasons for switching to fingolimod in patients relapsing-remitting multiple sclerosis in France: the ESGILE study.
Tourbah A; Papeix C; Tourniaire P; Rerat K; Meite M; Durand B; Lamy F; Chouette I; Mekies C;
Mult Scler Relat Disord; 2020 Nov; 46():102433. PubMed ID: 32862037
[TBL] [Abstract][Full Text] [Related]
30. Real-world effectiveness and safety of fingolimod in patients with multiple sclerosis in the Czech Republic: results from core and extension parts of the GOLEMS study up to 48 months.
Tichá V; Počíková Z; Vytlačil J; Štěpánová R
BMC Neurol; 2022 Apr; 22(1):143. PubMed ID: 35428205
[TBL] [Abstract][Full Text] [Related]
31. Aggressive cutaneous leishmaniasis in a patient with multiple sclerosis treated with fingolimod.
Hernández Clares R; Sánchez Pedreño P; García Vazquez E; Carreón Guarnizo E; Meca Lallana JE
Neurologia (Engl Ed); 2018 Jun; 33(5):348-349. PubMed ID: 28535923
[No Abstract] [Full Text] [Related]
32. Real-world retrospective study of effectiveness and safety of FINgOlimod in relapsing remitting multiple sclerosis in the Middle East and North Africa (FINOMENA).
Alroughani R; AlKawi Z; Hassan A; Al Otaibi H; Mujtaba A; Al Atat R; Riachi N; Akkawi N; Koussa S; Inshasi J; Alsaadi T; Ahmed SF; Al-Aasmi A; Zakaria M; El Fadally H
Clin Neurol Neurosurg; 2021 Apr; 203():106576. PubMed ID: 33714799
[TBL] [Abstract][Full Text] [Related]
33. Cryptococcal meningoencephalitis in an IgG
Wienemann T; Müller AK; MacKenzie C; Bielor C; Weyers V; Aktas O; Hartung HP; Kremer D
BMC Neurol; 2020 Apr; 20(1):158. PubMed ID: 32340606
[TBL] [Abstract][Full Text] [Related]
34. Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS.
Harris S; Tran JQ; Southworth H; Spencer CM; Cree BAC; Zamvil SS
Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32737072
[TBL] [Abstract][Full Text] [Related]
35. Lower lymphocyte counts and older age are associated with reduced multiple sclerosis disease activity during dimethyl fumarate treatment.
Garbo R; Lorenzut S; Del Negro I; Merlino G; Gigli GL; Cargnelutti D; Valente M
Mult Scler Relat Disord; 2021 Apr; 49():102781. PubMed ID: 33524927
[TBL] [Abstract][Full Text] [Related]
36. Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia.
Warnke C; Dehmel T; Ramanujam R; Holmen C; Nordin N; Wolfram K; Leussink VI; Hartung HP; Olsson T; Kieseier BC
Neurology; 2014 Dec; 83(23):2153-7. PubMed ID: 25361781
[TBL] [Abstract][Full Text] [Related]
37. Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients.
Kaufmann M; Haase R; Proschmann U; Ziemssen T; Akgün K
Front Immunol; 2018; 9():2669. PubMed ID: 30524432
[TBL] [Abstract][Full Text] [Related]
38. Delayed and recurrent dimethyl fumarate induced-lymphopenia in patients with multiple sclerosis.
Borrelli S; Mathias A; Goff GL; Pasquier RD; Théaudin M; Pot C
Mult Scler Relat Disord; 2022 Jul; 63():103887. PubMed ID: 35636269
[TBL] [Abstract][Full Text] [Related]
39. Comparative safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
Śladowska K; Kawalec P; Holko P; Osiecka O
Neurol Sci; 2022 Sep; 43(9):5479-5500. PubMed ID: 35713731
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness and safety of switching from fingolimod and natalizumab to rituximab in patients with relapsing remitting multiple sclerosis.
Fakih AU; Sahraian MA; Paybast S; Naser Moghadasi A
Mult Scler Relat Disord; 2023 Mar; 71():104564. PubMed ID: 36863084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
